Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIVASTIGMINE vs ROMOSOZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIVASTIGMINE vs ROMOSOZUMAB: Safety Overview

Metric RIVASTIGMINE ROMOSOZUMAB
Total FAERS Reports 9,123 434
Deaths Reported 2,232 48
Death Rate 24.5% 11.1%
Hospitalizations 2,716 81
Average Patient Age 80.0 yrs 69.1 yrs
% Female Patients 59.5% 94.5%
FDA Approval Date Apr 21, 2000 N/A
Manufacturer Novartis Pharmaceuticals Corporation Amgen, Inc
Route TRANSDERMAL SUBCUTANEOUS
Marketing Status Discontinued N/A